Cagrilintide combined with semaglutide (CagriSema) for treatment of type 2 diabetes In a recent small phase 2 trial (n=92), 3 groups of patients with type 2 diabetes were randomized to receive cagrilintide co-administered with semaglutide (the authors called this combination CagriSema), cagrilintide or semaglutide, both in doses escalated to 2.4 mg once weekly (table 1) [10]
Stable gastric pentadecapeptide BPC 157 studied for inflammatory bowel disease (PLD-116, PL14736, Pliva) induces nitric oxide synthesis
The Takeaway A BPC-157 peptide compounding pharmacy in Washington, DC provides access to this regenerative peptide for patients seeking support with recovery and repair
Another semaglutide injection, Wegovy, costs $1,848 per 4, 2.4 mg/0.75 mL autoinjector pens, which is also a one-month supply
HUBERMAN: And I want to point out something very important about this topic area
Informed by Robust Clinical Literature : Phase 1b, phase 2, and phase 3a programs have generated substantial data in obesity and type 2 diabetes research populations, helping guide mechanistic and translational study design